Associated Papers
Clinical and Genetic Landscape of Glioblastoma, IDH-Wildtype With FGFR Gene Family Alterations.
Kegoya Y et al.
Cancer Science, 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors.
Boni J et al.
The Embo Journal, 2025
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
Apfelbaum AA et al.
Nature Communications, 2025
Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.
Ziegler M et al.
Jco Precision Oncology, 2025
Activation of FGFR genes by genetic and epigenetic alterations in uterine leiomyomas.
Jokinen V et al.
Bjc Reports, 2025
A Hemorrhagic Brain Mass in a Child With Encephalocraniocutaneous Lipomatosis.
Hall E et al.
Journal of Pediatric Hematology/oncology, 2024
H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications.
Gestrich C et al.
Journal of Neuropathology and Experimental Neurology, 2023
Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers.
Brown LM et al.
Oncogene, 2023
Patient with Diffuse Midline Glioma, H3 K27-altered, Carrying an FGFR1 Mutation Who Experienced Thalamic Hemorrhage: A Case Report and Literature Review.
Matsunaga K et al.
Nmc Case Report Journal, 2023
The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer.
Trotman J et al.
British Journal of Cancer, 2022
FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM et al.
Pharmacology & Therapeutics, 2020
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
Lucas CG et al.
Acta Neuropathologica Communications, 2020
Actionable FGFR1 and BRAF mutations in adult circumscribed gliomas.
Trisolini E et al.
Journal of Neuro-oncology, 2019
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
Reinhardt A et al.
Acta Neuropathologica, 2018
FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.
Picca A et al.
Neurology, 2018
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM et al.
Plos Genetics, 2016
Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.
Schulte JD et al.
Neuro-oncology Advances, 0